Matrix Trust Company’s Avadel Pharmaceuticals AVDL Stock Holding History

Matrix Trust Company’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-573	Closed	-$12K	–	186
2025 Q4	$12K	Buy	+573	New	+$11.1K	﹤0.01%	196

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Matrix Trust Company's AVDL Position: Q1 2026 in Review

Matrix Trust Company sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 573 shares — an estimated $12K sold.

Matrix Trust Company first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $12K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Matrix Trust Company reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Matrix Trust Company sold 573 Avadel Pharmaceuticals shares in Q1 2026, an estimated $12K.
Matrix Trust Company first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Matrix Trust Company's Avadel Pharmaceuticals position peaked at $12K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Matrix Trust Company's 13F filing for Q1 2026, filed 10 Apr 2026.